PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER